Amgen (NASDAQ: AMGN) has announced plans to establish a new Science and Innovation Center at Genome Valley in Hyderabad, expanding the company’s global research and development capabilities. The new center will become part of Amgen’s global R&D network, which currently includes seven research laboratories. The facility is expected to strengthen the company’s ability to combine scientific research with data and digital technologies to support the discovery and development of new medicines.
Jay Bradner, MD, Executive Vice President of Research and Development, Artificial Intelligence and Data at Amgen, said the Hyderabad center will strengthen the integration of experimental science, data and technology across the company’s global research operations. He said connecting these capabilities will help Amgen accelerate research and translate scientific findings into medicines for patients.
The center is expected to become operational in 2027 and will bring together scientists and technology specialists working in discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. The Hyderabad team will collaborate closely with Amgen’s research facilities in other parts of the world.
Som Chattopadhyay, Senior Vice President of Global Business Solutions and National Executive at Amgen, said the new facility reflects the company’s commitment to scientific research and expands India’s role in its global R&D network. He added that the centre will support scientific collaboration while allowing Amgen to engage more closely with Hyderabad’s growing innovation ecosystem.
Genome Valley has developed into a major life sciences hub, supported by scientific talent, research infrastructure and a strong presence of pharmaceutical and biotechnology companies. The new Amgen facility will complement the company’s existing technology and innovation operations in Hyderabad.
Naveen Gullapalli, Managing Director, Amgen India, said Hyderabad’s life sciences ecosystem and STEM talent provide a strong base for combining biotechnology with digital technologies. He added that the new center will help Amgen advance research and contribute to the development of medicines for patients globally.
Telangana Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, D Sridhar Babu, welcomed the investment and said Amgen’s decision reflects Hyderabad’s growing importance as a global destination for advanced life sciences research. He said the city’s combination of scientific expertise, technology and industrial capabilities can support the development of new medicines and therapies for global markets.
The Science and Innovation Center will strengthen Amgen’s research capabilities in India while supporting collaboration across its international scientific network. The company plans to use the Hyderabad site to bring together laboratory research, advanced technologies, data and digital tools to improve the speed and precision of medicine development.
Amgen discovers, develops, manufactures and delivers medicines for serious diseases. For more than 45 years, the company has used biology, technology and human genetic data to advance research in areas including cancer, cardiovascular disease, inflammatory conditions, rare diseases and obesity-related conditions.
